{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:20:24Z","timestamp":1789730424476,"version":"4.0.1"},"reference-count":16,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,10,9]],"date-time":"2022-10-09T00:00:00Z","timestamp":1665273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018731","name":"Jiangsu Hengrui Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                    <jats:label\/>\n                    <jats:p>To evaluate the pharmacokinetic effects of SHR3680 on repaglinide and bupropion and its metabolite hydroxybupropion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single\u2010centre, open\u2010label, single\u2010arm, fixed\u2010sequence clinical trial in 18 patients with prostate cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After a single oral dose of 0.5\u00a0mg repaglinide and SHR3680, geometric mean peak plasma concentration (C\n                      <jats:sub>max<\/jats:sub>\n                      ) of plasma repaglinide was 14.240 and 5.887\u2009ng\/mL, geometric mean area under the concentration\u2013time curve (AUC\n                      <jats:sub>0\u2013t<\/jats:sub>\n                      )was 20.577 and 7.320\u2009h\u00a0ng\/mL, geometric mean AUC\n                      <jats:sub>0\u2013\u221e<\/jats:sub>\n                      was 20.949 and 7.451\u2009h\u00a0ng\/mL, mean half\u2010life (t\n                      <jats:sub>1\/2<\/jats:sub>\n                      ) was 1.629 and 1.195\u2009hours, and geometric mean oral clearance (CL\/F) was 23.867 and 67.107\u2009L\/h, respectively. After a single oral administration of 150\u2009mg bupropion and SHR3680, geometric mean C\n                      <jats:sub>max<\/jats:sub>\n                      of plasma bupropion was 85.430 and 33.747\u2009ng\/mL, geometric mean AUC\n                      <jats:sub>0\u2013t<\/jats:sub>\n                      was 1003.896 and 380.158\u2009h\u00a0ng\/mL, geometric mean AUC\n                      <jats:sub>0\u2013\u221e<\/jats:sub>\n                      was 1038.054 and 401.387\u2009h\u00a0ng\/mL, mean t\n                      <jats:sub>1\/2<\/jats:sub>\n                      was 22.533 and 17.733\u2009hours, and geometric mean CL\/F was 144.501 and 373.705\u2009L\/h, respectively. The plasma geometric mean C\n                      <jats:sub>max<\/jats:sub>\n                      of its main active metabolic hydroxybupropion was 268.113 and 177.318\u2009ng\/mL, geometric mean AUC\n                      <jats:sub>0\u2013t<\/jats:sub>\n                      was 14\u2009283.087 and 5420.219\u2009h\u00a0ng\/mL, geometric mean AUC\n                      <jats:sub>0\u2013\u221e<\/jats:sub>\n                      was 15\u2009218.158 and 5364.625\u2009h\u00a0ng\/mL, mean t\n                      <jats:sub>1\/2<\/jats:sub>\n                      were 36.069 and 16.688\u2009hours, and geometric mean CL\/F was 8.623\u2009L\/h and 27.961\u2009L\/h, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Coadministration of SHR3680 with repaglinide or bupropion significantly shortened the elimination half\u2010lives, significantly increased the apparent clearance rate, and significantly decreased the in vivo exposure of repaglinide, bupropion and hydroxybupropion compared with single administration of repaglinide or bupropion.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bcp.15528","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T08:08:08Z","timestamp":1663056488000},"page":"874-886","source":"Crossref","is-referenced-by-count":6,"title":["A single\u2010centre, open\u2010label, single\u2010arm, fixed\u2010sequence pharmacokinetic study of SHR3680 on repaglinide and bupropion in prostate cancer patients"],"prefix":"10.1111","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8251-4088","authenticated-orcid":false,"given":"Tao","family":"Dai","sequence":"first","affiliation":[{"name":"Urology Surgery Department, Hunan Cancer Hospital\/The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University  Changsha China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhou","family":"Xu","sequence":"additional","affiliation":[{"name":"Urology Surgery Department, Hunan Cancer Hospital\/The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University  Changsha China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Huang","sequence":"additional","affiliation":[{"name":"Urology Surgery Department, Hunan Cancer Hospital\/The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University  Changsha China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yike","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology Jiangsu Hengrui Pharmaceuticals Co., Ltd.  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gongqian","family":"Zeng","sequence":"additional","affiliation":[{"name":"Urology Surgery Department, Hunan Cancer Hospital\/The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University  Changsha China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingji","family":"Ye","sequence":"additional","affiliation":[{"name":"Urology Surgery Department, Hunan Cancer Hospital\/The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University  Changsha China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Liu","sequence":"additional","affiliation":[{"name":"Urology Surgery Department, Hunan Cancer Hospital\/The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University  Changsha China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuhua","family":"Zeng","sequence":"additional","affiliation":[{"name":"Urology Surgery Department, Hunan Cancer Hospital\/The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University  Changsha China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusuan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Urology Surgery Department, Hunan Cancer Hospital\/The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University  Changsha China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqing","family":"Han","sequence":"additional","affiliation":[{"name":"Urology Surgery Department, Hunan Cancer Hospital\/The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University  Changsha China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingying","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Medicine Clinical Laboratory The Third Xiangya Hospital of Central South University  Changsha China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,10,9]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.22.4.232"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.4777"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1168175"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1207506"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916\u2010022\u201002263\u2010x"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.5005"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405095"},{"key":"e_1_2_11_10_1","unstructured":"Food and Drug Administration.In vitro drug interaction studies\u2014cytochrome P450 enzyme\u2010 and transporter\u2010mediated drug interactions guidance for industry.2020."},{"key":"e_1_2_11_11_1","unstructured":"Food and Drug Administration.Clinical drug interaction studies\u2014cytochrome P450 enzyme\u2010 and transporter\u2010mediated Drug interactions guidance for industry.2020."},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13877"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13425"},{"key":"e_1_2_11_14_1","unstructured":"European Medicines Agency.Guideline on the investigation of drug interactions.2012."},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.116.071076"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010021\u201004292\u20104"},{"key":"e_1_2_11_17_1","doi-asserted-by":"crossref","unstructured":"LiT LiX JiangX et al.The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects. Authorea. April 27 2022.","DOI":"10.22541\/au.165107710.09984227\/v1"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15528","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15528","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15528","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T04:44:15Z","timestamp":1692506655000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,9]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1111\/bcp.15528"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15528","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,9]]}}}